Cargando…

Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis

PURPOSE: We conducted a literature-based meta-analysis of the risk of cardiovascular toxicities associated with MEK inhibitors. METHODS: Eligible trials included randomized phase II and III trials of patients with cancer who were given a mitogen activated protein (MAP)/extracellular signal-regulated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdel-Rahman, Omar, ElHalawani, Hesham, Ahmed, Hoda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2015
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539872/ https://www.ncbi.nlm.nih.gov/pubmed/28804776 http://dx.doi.org/10.1200/JGO.2015.000802

Ejemplares similares

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States
por: Abdel-Rahman, Omar, et al.
Publicado: (2018)

Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review
por: Glen, Claire, et al.
Publicado: (2022)

Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis
por: Mincu, Raluca I., et al.
Publicado: (2019)

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
por: Klesse, Laura J., et al.
Publicado: (2020)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease
por: Saunders, Ila M., et al.
Publicado: (2019)

Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity
por: Gadiot, Jules, et al.
Publicado: (2013)

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
por: Liu, Yahong, et al.
Publicado: (2023)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
por: Ismail, Rawa K., et al.
Publicado: (2022)

Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma
por: Homan, Morgan, et al.
Publicado: (2022)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Current Development Status of MEK Inhibitors
por: Cheng, Ying, et al.
Publicado: (2017)

Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors
por: Ohm, Hyejee, et al.
Publicado: (2023)

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
por: Bendell, Johanna C, et al.
Publicado: (2017)

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
por: Küsters-Vandevelde, Heidi VN, et al.
Publicado: (2014)

A Case of Non-Resolving MEK Inhibitor-Associated Retinopathy
por: Chancellor, John R., et al.
Publicado: (2019)

Kaposiform lymphangiomatosis effectively treated with MEK inhibition
por: Foster, Jessica B, et al.
Publicado: (2020)

Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors
por: Otieno, Steve Biko, et al.
Publicado: (2020)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient
por: Boutros, Andrea, et al.
Publicado: (2020)

LGG-62. Weight change in pediatric patients treated with MEK inhibitors: a retrospective cohort study
por: Hyun Bahng, Hye, et al.
Publicado: (2022)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xavier, Camila Bragança, et al.
Publicado: (2022)

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
por: Louveau, Baptiste, et al.
Publicado: (2019)

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
por: Yoshida, Takayuki, et al.
Publicado: (2012)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma
por: Chang-Yew Leow, C, et al.
Publicado: (2013)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901
por: Shannon, Stephen, et al.
Publicado: (2017)

ETS-targeted therapy: can it substitute for MEK inhibitors?
por: Tetsu, Osamu, et al.
Publicado: (2017)

Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response
por: Gonzalez-Cao, Maria, et al.
Publicado: (2016)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
por: Mezi, Silvia, et al.
Publicado: (2023)

Atrial Fibrillation in Heart Failure with Preserved Left Ventricular Systolic Function: Distinct Elevated Risk for Cardiovascular Outcomes in Women Compared to Men
por: Omar, Alaa Mabrouk Salem, et al.
Publicado: (2022)

LGG-17. CLINICAL OUTCOME OF PEDIATRIC LOW GRADE GLIOMA WITH POSITIVE BRAF-FUSION TREATED WITH MEK INHIBITOR
por: Dennis, T L Ku, et al.
Publicado: (2021)

MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?
por: El Darsa, Haidar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h115krkdkv8q4gr0716qba4j28